An Update on Axsome Therapeutics, Inc. (NASDAQ:AXSM)
New York, New York, 08:30 EST Jan 17, 2017 (NetworkNewsWire) – Once New York-based Axsome Therapeutics, Inc. (
NASDAQ:AXSM) was founded in 2012, its team set out to establish a fully-integrated biopharmaceutical business that would develop therapies to treat and manage central nervous system (CNS) disorders. Now in 2017, the Axsome team is setting off on another exciting leg on this journey.
For years, Axsome has been laser-focused on improving the lives of patients living with pain and various CNS disorders. With an eye toward differentiated therapies, the company has concentrated on developing and commercializing both in-licensed drug candidates and internally-derived drug candidates in order to accomplish its goal of increasing the treatment options accessible to caregivers.
Along the way, industry analysts have pointed out the value in Axsome’s focus on complex regional pain syndrome, treatment resistant depression and agitation in patients with Alzheimer’s disease (AD); the lower-than-average research and development risks, as well as the tested business models that surround these disorders, hint at a faster commercialization schedule.
During the first week of 2017, a new report from AEGIS Capital Corp. (http://nnw.fm/918Lb) also alluded to Axsome’s accelerated timeline and other investment highlights, including recent developments affecting one of the company’s two late-stage drug candidates: AXS-05, a fixed-dose combination of dextromethorphan and bupropion that is being developed for multiple indications, including treatment resistant depression and agitation in patients with AD.
According to the AEGIS report, on January 4, 2017, Axsome announced that the United States’ Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for a phase II/III clinical trial of AXS-05 in AD. This is a significant development for the company, as this IND program is the means by which a pharmaceutical company operating within the United States obtains permission to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved. With the FDA’s approval in tow, the placebo-controlled, randomized, double-blind, multicenter trial is now set to register the necessary 330 patients and to commence sometime in the first half of 2017.
For more information, visit www.Axsome.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer.
Source:NetworkNewsWire
Contact:
NetworkNewsWire (NNW) New York, New York www.NetworkNewsWire.com 212.418.1217 Office Editor@NetworkNewsWire.com
